Cost-effectiveness of adjuvanted influenza vaccination of healthy children 6 to 60 months of age

Monia Marchetti, Ursula M. Kühnel, Giorgio L. Colombo, Susanna Esposito, Nicola Principi

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

This study estimated the health and economic outcomes of universal administration of a adjuvanted influenza vaccine to healthy preschool children, as compared with current immunization practice. A Markov model simulated a cohort of 3 million children and their households undergoing five influenza seasons. Assuming a vaccine uptake rate of 30%, at the current acquisition cost of €5.50 per vaccine dose influenza vaccination (two doses for unprimed children) of 6- to 60-month- (5-year) old children averted more than 1 million clinical influenza episodes and saved €63 million, from the perspective of the Italian society. From the perspective of the Italian health care service, influenza vaccination of 6- to 60- and of 6- to 24-month-old children cost €10,000 and €13,333 per quality-adjusted life year (QALY) saved, respectively. Administration of a adjuvanted influenza vaccine to children aged 6 to 60 months was highly cost-effective for the health care service and cost saving for the society.

Original languageEnglish
Pages (from-to)14-22
Number of pages9
JournalHuman Vaccines
Volume3
Issue number1
Publication statusPublished - Jan 2007

Fingerprint

Human Influenza
Cost-Benefit Analysis
Vaccination
Influenza Vaccines
Costs and Cost Analysis
Health Services
Quality-Adjusted Life Years
Preschool Children
Health Care Costs
Immunization
Vaccines
Economics
Delivery of Health Care
Health

Keywords

  • 6 to 60-month-old children
  • Cost-effectiveness
  • Virosomal adjuvanted influenza vaccine

ASJC Scopus subject areas

  • Immunology
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Marchetti, M., Kühnel, U. M., Colombo, G. L., Esposito, S., & Principi, N. (2007). Cost-effectiveness of adjuvanted influenza vaccination of healthy children 6 to 60 months of age. Human Vaccines, 3(1), 14-22.

Cost-effectiveness of adjuvanted influenza vaccination of healthy children 6 to 60 months of age. / Marchetti, Monia; Kühnel, Ursula M.; Colombo, Giorgio L.; Esposito, Susanna; Principi, Nicola.

In: Human Vaccines, Vol. 3, No. 1, 01.2007, p. 14-22.

Research output: Contribution to journalArticle

Marchetti, M, Kühnel, UM, Colombo, GL, Esposito, S & Principi, N 2007, 'Cost-effectiveness of adjuvanted influenza vaccination of healthy children 6 to 60 months of age', Human Vaccines, vol. 3, no. 1, pp. 14-22.
Marchetti M, Kühnel UM, Colombo GL, Esposito S, Principi N. Cost-effectiveness of adjuvanted influenza vaccination of healthy children 6 to 60 months of age. Human Vaccines. 2007 Jan;3(1):14-22.
Marchetti, Monia ; Kühnel, Ursula M. ; Colombo, Giorgio L. ; Esposito, Susanna ; Principi, Nicola. / Cost-effectiveness of adjuvanted influenza vaccination of healthy children 6 to 60 months of age. In: Human Vaccines. 2007 ; Vol. 3, No. 1. pp. 14-22.
@article{ceb6bf3d5d7b4311af642891041590fd,
title = "Cost-effectiveness of adjuvanted influenza vaccination of healthy children 6 to 60 months of age",
abstract = "This study estimated the health and economic outcomes of universal administration of a adjuvanted influenza vaccine to healthy preschool children, as compared with current immunization practice. A Markov model simulated a cohort of 3 million children and their households undergoing five influenza seasons. Assuming a vaccine uptake rate of 30{\%}, at the current acquisition cost of €5.50 per vaccine dose influenza vaccination (two doses for unprimed children) of 6- to 60-month- (5-year) old children averted more than 1 million clinical influenza episodes and saved €63 million, from the perspective of the Italian society. From the perspective of the Italian health care service, influenza vaccination of 6- to 60- and of 6- to 24-month-old children cost €10,000 and €13,333 per quality-adjusted life year (QALY) saved, respectively. Administration of a adjuvanted influenza vaccine to children aged 6 to 60 months was highly cost-effective for the health care service and cost saving for the society.",
keywords = "6 to 60-month-old children, Cost-effectiveness, Virosomal adjuvanted influenza vaccine",
author = "Monia Marchetti and K{\"u}hnel, {Ursula M.} and Colombo, {Giorgio L.} and Susanna Esposito and Nicola Principi",
year = "2007",
month = "1",
language = "English",
volume = "3",
pages = "14--22",
journal = "Human Vaccines",
issn = "1554-8600",
publisher = "Landes Bioscience",
number = "1",

}

TY - JOUR

T1 - Cost-effectiveness of adjuvanted influenza vaccination of healthy children 6 to 60 months of age

AU - Marchetti, Monia

AU - Kühnel, Ursula M.

AU - Colombo, Giorgio L.

AU - Esposito, Susanna

AU - Principi, Nicola

PY - 2007/1

Y1 - 2007/1

N2 - This study estimated the health and economic outcomes of universal administration of a adjuvanted influenza vaccine to healthy preschool children, as compared with current immunization practice. A Markov model simulated a cohort of 3 million children and their households undergoing five influenza seasons. Assuming a vaccine uptake rate of 30%, at the current acquisition cost of €5.50 per vaccine dose influenza vaccination (two doses for unprimed children) of 6- to 60-month- (5-year) old children averted more than 1 million clinical influenza episodes and saved €63 million, from the perspective of the Italian society. From the perspective of the Italian health care service, influenza vaccination of 6- to 60- and of 6- to 24-month-old children cost €10,000 and €13,333 per quality-adjusted life year (QALY) saved, respectively. Administration of a adjuvanted influenza vaccine to children aged 6 to 60 months was highly cost-effective for the health care service and cost saving for the society.

AB - This study estimated the health and economic outcomes of universal administration of a adjuvanted influenza vaccine to healthy preschool children, as compared with current immunization practice. A Markov model simulated a cohort of 3 million children and their households undergoing five influenza seasons. Assuming a vaccine uptake rate of 30%, at the current acquisition cost of €5.50 per vaccine dose influenza vaccination (two doses for unprimed children) of 6- to 60-month- (5-year) old children averted more than 1 million clinical influenza episodes and saved €63 million, from the perspective of the Italian society. From the perspective of the Italian health care service, influenza vaccination of 6- to 60- and of 6- to 24-month-old children cost €10,000 and €13,333 per quality-adjusted life year (QALY) saved, respectively. Administration of a adjuvanted influenza vaccine to children aged 6 to 60 months was highly cost-effective for the health care service and cost saving for the society.

KW - 6 to 60-month-old children

KW - Cost-effectiveness

KW - Virosomal adjuvanted influenza vaccine

UR - http://www.scopus.com/inward/record.url?scp=33847010239&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847010239&partnerID=8YFLogxK

M3 - Article

VL - 3

SP - 14

EP - 22

JO - Human Vaccines

JF - Human Vaccines

SN - 1554-8600

IS - 1

ER -